Status:
COMPLETED
An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
Lead Sponsor:
Sanofi
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a Phase 1, multi-center, open-label study. During Segment 1, patients are administered a single IV administration of \[14C\]-iniparib. During Segment 2, patients are administered iniparib wi...
Eligibility Criteria
Inclusion
- Male or female patients with advanced solid tumors that are refractory to standard treatment or for which no standard treatment exists; patients must be at least 18 years old.
- Additional criteria are also required and should be evaluated by the research staff.
Exclusion
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01161836
Start Date
July 1 2010
End Date
June 1 2011
Last Update
September 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwest Medical Specialties
Tacoma, Washington, United States, 98405